Announcements
- Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update
- Addex Convenes Annual General Meeting 2024
- Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
- Addex to Present at Bio€quity Europe 2024
- Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
- Addex to Present at the Swiss Biotech Day 2024
- Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
- Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
- Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
- Addex to Present at the Bio-Europe Spring 2024 Conference
More ▼
Key statistics
On Friday, Addex Therapeutics Ltd (APE1:DUS) closed at 7.70, -5.52% below its post-IPO high of 8.15, set on May 29, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.30 |
---|---|
High | 7.70 |
Low | 7.25 |
Bid | 7.70 |
Offer | 9.15 |
Previous close | 7.35 |
Average volume | 0.00 |
---|---|
Shares outstanding | 1.54m |
Free float | 725.97k |
P/E (TTM) | -- |
Market cap | 13.46m USD |
EPS (TTM) | -15.04 USD |
Data delayed at least 15 minutes, as of Jun 14 2024 18:32 BST.
More ▼